Pressmeddelanden

Läs mer:

Kategorier

RSS

2015

2015-09-30 13:26 Nyemissionen i Nanologica AB (publ) övertecknades

Nyemissionen om 22,0 MSEK som genomförs inför listning på AktieTorget tecknades till ca 150 procent. Det stora intresset medför att...

2015-09-07 13:06 Nanologica AB (publ) offentliggör prospekt gällande nyemission och notering på AktieTorget

Nanologica offentliggör härmed prospektet gällande nyemissionen. Prospektet har godkänts och registrerats hos Finansinspektionen. Nanologica...

2015-04-29 13:47 Årsredovisning 2014 Regulatory

2014

2014-03-31 13:44 Årsredovisning 2013 Regulatory

2013

2013-05-23 13:42 Årsredovisning 2012 Regulatory

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.